These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 33107920

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.
    Abdel-Fatah TMA, Ball GR, Thangavelu PU, Reid LE, McCart Reed AE, Saunus JM, Duijf PHG, Simpson PT, Lakhani SR, Pongor L, Gyorffy B, Moseley PM, Green AR, Pockley AG, Caldas C, Ellis IO, Chan SYT.
    JAMA Netw Open; 2020 Jul 01; 3(7):e209486. PubMed ID: 32633764
    [Abstract] [Full Text] [Related]

  • 4. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
    Wang X, Cai L, Ye F, Li M, Ma L, Geng C, Song Z, Liu Y.
    Medicine (Baltimore); 2019 Sep 01; 98(36):e16937. PubMed ID: 31490377
    [Abstract] [Full Text] [Related]

  • 5. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S, Huang L, Chen CM, Shao ZM.
    Oncotarget; 2015 Jul 20; 6(20):18174-82. PubMed ID: 26053183
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 Jul 20; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 20; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 8. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H.
    Breast Cancer; 2015 May 20; 22(3):308-16. PubMed ID: 23771556
    [Abstract] [Full Text] [Related]

  • 9. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.
    Breast Cancer; 2015 Mar 20; 22(2):185-91. PubMed ID: 23645542
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
    Huang L, Chen T, Chen C, Chen S, Liu Y, Wu J, Shao Z.
    World J Surg Oncol; 2013 Nov 30; 11():307. PubMed ID: 24289519
    [Abstract] [Full Text] [Related]

  • 13. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Mitra D, Bhattacharyya S, Alam N, Sen S, Mitra S, Mandal S, Vignesh S, Majumder B, Murmu N.
    Breast Cancer Res Treat; 2020 Jan 30; 179(2):359-370. PubMed ID: 31686261
    [Abstract] [Full Text] [Related]

  • 14. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S.
    JAMA Oncol; 2015 Jul 30; 1(4):448-54. PubMed ID: 26181252
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
    Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Nov 01; 7():203. PubMed ID: 17976237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.